Overview

Gadolinium Contrast-enhanced Abbreviated MRI (AMRI) vs. Standard Ultrasound for Hepatocellular Carcinoma (HCC) Surveillance in Patients With Cirrhosis

Status:
Recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

This study compares gadolinium contrast-enhanced Abbreviated MRI (AMRI) to standard ultrasound for Hepatocellular Carcinoma (HCC) screening and surveillance in subjects with liver cirrhosis.

Phase:

Phase 4

Details

Lead Sponsor:

University of California, San Diego

Collaborators:

Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma
Icahn School of Medicine at Mount Sinai

Treatments:

Diethylenetriamine
Edetic Acid
Pentetic Acid